Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOFIINGO: Transition from Natalizumab to Fingolimod in RRMS
NCT01499667Phase 3Terminated
- Sponsor
- Novartis
- Start
- Sep 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of fingolimod in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Novartis. Primary endpoint: Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment. Started Sep 2011; status: terminated.
02
Drugs
fingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01499667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01499667.